Supplemental Figure 1. Human melanoma cells secrete VEGF which is effectively neutralized by bevacizumab. A. Baseline VEGF secretion was measured across 11 human melanoma-derived cell lines using the human VEGF Quantikine ELISA kits by R&D systems. B,C. VEGF levels were measured in the high-VEGF secreting DM443 and low-VEGF secreting DM738 using the human VEGF Quantikine ELISA kits 24-72 hours after treatment with 0.5 to 2.0 mg/mL bevacizumab, demonstrating complete neutralization at all concentrations of bevacizumab.

Supplemental Figure 2. Bevacizumab does not alter in vitro LPAM chemosensitivity.

High VEGF-secreting DM443 (A) and low VEGF-secreting DM738 (B) were treated with 0.5 to 2.0 mg/mL bevacizumab and 0-150 µM LPAM. Cell viability was measured 72 hours after treatment and used to determine fraction of surviving cells. No differences in LPAM chemosensitivity were observed in vitro.